Study Highlights:

  • A noninvasive neurotechnology that identifies and translates unbalancedbrain electrical activity into audible tones was associatedlower blood pressure and improved heart rate variability.
  • The same technology reduced self-reported disability from migraines and associated sleep and mood disorders.

Embargoed until 1pm ET Thursday, Sept. 15, 2016

ORLANDO, Florida, Sept. 15, 2016 — A noninvasive neurotechnology, which uses sound to balance right- and left-side brain frequencies was associated with lowered blood pressure, improved heart rate variability, and reduced symptoms of migraine headaches, according to two small studies presented at the American Heart Association’s Council on Hypertension 2016 Scientific Sessions.

The neurotechnology, called High-resolution, relational, resonance based, electroencephalic mirroring, or HIRREM® (Brain State Technologies, Scottsdale, Arizona), uses sensors placed on the scalp to measure brain electrical activity, and detect right/left imbalances, or hyperarousal, according to study author Hossam A. Shaltout, R.Ph., Ph.D., assistant professor in the Hypertension and Vascular Research Center at Wake Forest School of Medicine in Winston-Salem, North Carolina.

“Most people have relatively balanced electrical activity between the right side and left sides of the brain,” Shaltout said. “Imbalance, with one side dominant, or more active, may reflect autonomic dysregulation associated with the effects of chronic stress, which is thought to play a role in high blood pressure, migraines, insomnia, depression, hot flashes and more.”

In real time, HIRREM monitors brain electrical activity and translates dominant brain frequencies into computer-generated audible tones that are reflected back simultaneously via ear buds.

“Gradually, and on its own, with no conscious, cognitive activity required, the electrical pattern tends to shift towards improved balance and reduced hyperarousal,” Shaltout said.

In one study (Abstract P310), researchers looked at HIRREM’s impact on 10 men and women with stage one hypertension at the start of the study. After an average of 17.7 HIRREM sessions received over 10.2 in-office days, hypertensive patients showed an average reduction in their systolic blood pressure, from 152 to 136 millimeters of mercury (mm Hg), and a reduction in their diastolic pressure from 97 to 81 mmHg.

Insomnia severity improved in the small study group, and anxiety seemed to improve. The researchers also found that heart rate variability increased from an average 42 to 57 milliseconds, which is a good thing, Shaltout said. Heart rate variability refers to variations in the interval between heartbeats.

“The more flexibility and dynamic range the body has to be able to change the heart rate in response to the blood pressure, the better,” Shaltout said.

In another study (Abstract P602), the researchers examined the effect of HIRREM on 52 adults who had reported they suffered from migraines. The patients studied received 15.9 sessions over nine in-office days. Comparing the data they collected before the therapy to two weeks after, researchers found patients reported improvements for insomnia, mood, and headaches.

These results are the first to suggest that HIRREM could offer cardiovascular as well as behavioral benefits in the treatment of high blood pressure. More research is needed to verify these preliminary findings, Shaltout said.

These studies looking at hypertension and migraine are part of a larger research program that has now enrolled over 400 participants in one of five studies to assess the effect of HIRREM for multiple symptoms and conditions,.

“If these findings are confirmed in larger controlled studies, HIRREM may prove to be a valuable new approach for brain-based health care,” Shaltout said.

Co-authors on both abstracts are Catherine L. Tegeler, B.S.; Charles H. Tegeler, M.D. and Sung Lee, M.D., M.Sc. Author disclosures are on the abstract.

The Susanne Marcus Collins Foundation, Inc., funded the study.

Additional Resources:


Statements and conclusions of study authors that are presented at American Heart Association scientific meetings are solely those of the study authors and do not necessarily reflect association policy or position. The association makes no representation or warranty as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at

For Media Inquiries: (214) 706-1173

Maggie Francis: (214) 706-1382;

Julie Del Barto (broadcast): (214) 706-1330;

For Public Inquiries: (800) AHA-USA1 (242-8721) and

Life is why, science is how . . .  we help people live longer, healthier lives.